Short reportsInterleukin-10 production during septicaemia
References (9)
- et al.
Modified immunological status of anti-IL-10 treated mice
Cell Immunol
(1993) - et al.
Septic shock: pathogenesis
Lancet
(1991) - et al.
Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes
J Exp Med
(1991) - et al.
Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide
Eur J Immunol
(1993)
There are more references available in the full text version of this article.
Cited by (312)
Immunotherapy in sepsis - brake or accelerate?
2020, Pharmacology and TherapeuticsCitation Excerpt :Sepsis involves not only excessive inflammation but also several molecular and cellular events that support immunosuppression (Hotchkiss, Monneret, & Payen, 2013b). One example is the release of anti-inflammatory mediators such as IL-10, IL-1 receptor antagonist (RA) or transforming growth factor beta (TGFβ) by immune cells (Cavaillon, Adib-Conquy, Fitting, Adrie, & Payen, 2003; Goldie et al., 1995; Marchant et al., 1994; Marie, Cavaillon, & Losser, 1996). While these processes may help rebalance the immune system, over-exuberant immune suppression can be harmful to critically ill patients by allowing for the development of secondary infections and subsequent multi-organ failure (Gentile et al., 2012).
Kinetics of plasma procalcitonin, soluble CD14, CCL2 and IL-10 after a sublethal infusion of lipopolysaccharide in horses
2017, Veterinary Immunology and ImmunopathologyIndividual gene expression and personalised medicine in sepsis
2016, The Lancet Respiratory Medicine
Copyright © 1994 Published by Elsevier Ltd.